SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): September 1,
2010
NEOSTEM,
INC.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
0-10909
(Commission
File
Number)
|
22-2343568
(IRS
Employer
Identification
No.)
|
420 Lexington Avenue, Suite
450, New York, New York 10170
(Address
of Principal Executive Offices)(Zip Code)
(212)
584-4180
Registrant's
Telephone Number
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other Events
Effective as of September 1, 2010,
NeoStem, Inc. (the “Company”) appointed Ian Zhang, Ph.D., MBA, age 45, as the
President and Managing Director of NeoStem (China), Inc., a wholly foreign owned
subsidiary of the Company. A copy of the Company’s press release dated
September 7, 2010 relating to Dr. Zhang’s appointment is attached hereto as
Exhibit 99.1 and incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
release, dated September 7, 2010
|
-2-
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this Report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
NEOSTEM,
INC.
|
|||
|
By:
|
/s/
Catherine M. Vaczy
|
||
|
Name:
Catherine M. Vaczy
|
|||
|
Title:
Vice President and General Counsel
|
|||
Date: September
8, 2010
-3-
NeoStem
Appoints Distinguished Businessman as New President and Managing Director
NeoStem China
Dr.
Ian Zhang has over 20 years of experience in the biotech field
Press Release Source: NeoStem,
Inc. On Tuesday September 7, 2010, 8:30 am EDT
NEW YORK,
Sept. 7 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or
the "Company"), an international biopharmaceutical company with operations in
the U.S. and China, today announced that it has appointed Ian Zhang, Ph.D., MBA,
as the new president and managing director of NeoStem (China), Inc. Dr.
Zhang is the former Head of Asia Pacific Integration at Life Technologies, where
he served on the steering committee managing the acquisition and integration of
Applied BioSystems. He is also the former Head of Corporate Development
(Asia Pacific) for Invitrogen responsible for growth strategy and acquisitions
and integrations, where he had also managed the acquisition and integration of
BioAsia, Dynal, Zymed, and Caltech by Invitrogen. Dr. Zhang also served as
the President and General Manager for Dynal Biotech (Beijing) Ltd. (a wholly
owned subsidiary of Invitrogen Corporation).
Dr. Zhang
received his MBA at the University of Chicago, Graduate School of Business and
holds a Ph.D. in biotechnology from Simon Fraser University. He continued
his education as a postdoctoral fellow at Yale University School of Medicine.
His professional focus is on growth strategy and acquisitions/integrations
in the biotech field particularly related to biotech growth in Asia. "Now that
we have launched our business in China and are generating revenues, we are
excited to add such a seasoned individual to our senior management team to lead
the expansion effort," said Dr. Robin Smith, CEO and Chairman of the Board of
NeoStem.
Dr. Zhang
commented, "I am excited to join an innovative, forward-looking company like
NeoStem and be part of the team of experts to help bring advanced stem cell
technologies into China and develop a business in China in a regulatory
environment that is supportive of Stem Cells and a healthcare environment that
can benefit from technologies to treat diseases using stem cell based
therapy."
About
NeoStem, Inc.
NeoStem,
Inc. is engaged in the development of stem cell-based therapies and building of
a network of adult stem cell collection centers in the U.S. and China that are
focused on enabling people to donate and store their own (autologous) stem cells
for their personal use in times of future medical need. The Company is also the
licensee of various stem cell technologies, including a worldwide exclusive
license to VSEL™ Technology which uses very small embryonic-like stem cells,
shown to have several physical characteristics that are generally found in
embryonic stem cells, and is pursuing the licensing of other technologies for
therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation,
Suzhou Erye, manufactures and distributes generic antibiotics in China. For more
information, please visit: http://www.neostem.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
reflect management's current expectations, as of the date of this press release,
and involve certain risks and uncertainties. Forward looking statements include
the future of VSEL TM Technology as a viable treatment option, about which no
assurances can be given. The Company's actual results could differ materially
from those anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to materially differ
from the recent results or those projected in forward-looking statements include
the "Risk Factors" described in the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March 31, 2010, as
well as other periodic and other filings made with the Securities and Exchange
Commission. The Company's further development is highly dependent on future
medical and research developments and market acceptance, which is outside its
control.
|
NeoStem,
Inc.
|
|
|
Robin
Smith, CEO
|
|
|
Phone:
+1 (212) 584-4174
|
|
|
E-mail: rsmith@neostem.com
|
|
|
http://www.neostem.com
|